Quarterly report pursuant to Section 13 or 15(d)

Discontinuing Operations - Summarized results of consolidated discontinued operations (Details)

v3.20.1
Discontinuing Operations - Summarized results of consolidated discontinued operations (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Income Statement Information      
Revenue $ 0 $ 5,017  
Cost of revenues 0 3,635  
Gross profit 0 1,382  
Research and development 0 454  
General and administrative (8) 1,527  
Sales and marketing 0 923  
Transaction costs 0 249  
Total operating expenses (8) 3,153  
Income (loss) from discontinuing operations 8 (1,771)  
Interest expense 0 (1,110)  
Total other income (expense) 0 (1,110)  
Net income (loss) from discontinuing operations 8 (2,881)  
Current assets of discontinuing operations:      
Accounts receivable, net of allowance for doubtful accounts of $4,518 in 2020; $4,536 in 2019 0   $ 71
Allowance for doubtful accounts 4,518   4,536
Current assets of discontinuing operations 0   71
Current liabilities of discontinuing operations      
Accounts payable and accrued expenses 764   1,137
Due to Interpace Biosciences, Inc. 97   92
Current liabilities of discontinuing operations 861   $ 1,229
Cash Flow Information      
Income (loss) from discontinuing operations 8 (2,881)  
Adjustments to reconcile income (loss) from discontinuing operations to net cash used in operating activities, discontinuing operations      
Depreciation 0 256  
Amortization 0 6  
Provision for bad debts (18) 0  
Accounts payable settlements (26) 0  
Stock-based compensation 0 39  
Amortization of operating lease right-of-use assets 0 94  
Amortization of discount of debt and debt issuance costs 0 593  
Interest added to Convertible Note 0 113  
Change in working capital components:      
Accounts receivable 89 (151)  
Other current assets 0 (272)  
Other non-current assets 0 (1)  
Accounts payable, accrued expenses and deferred revenue (347) (942)  
Obligations under operating leases 0 (31)  
Deferred rent payable and other 0 (151)  
Due to Interpace Biosciences, Inc. 5 0  
Net cash used in operating activities, discontinuing operations $ (289) $ (3,328)